Gene Network Sciences Announces Research Collaboration with CombinatoRx
Complete the form below to unlock access to ALL audio articles.
Gene Network Sciences, Inc. (GNS) has announced that it has entered into an agreement with CombinatoRx, Incorporated (CRXX) to contribute to ongoing mechanism of action research for synergistic combinations in development. Financial terms of the agreement were not disclosed.
Under the agreement, the parties will use protein expression and transcriptional profiling data generated by CRXX and the GNS proprietary REFS™ (reverse engineering and forward simulation) software platform to characterize unanticipated mechanisms underlying the synergistic interactions between the components of multi-target therapeutic candidates.
Combination effects are often caused by non-obvious interactions between biological targets and signaling pathways that can be uncovered using the REFS™ technology. This is the second agreement that GNS has announced in the critical area of understanding drug combinations and synergies in 2007.
Earlier this year, GNS entered into an agreement with Weill Cornell Medical College to characterize the synergies between two commonly used classes of cancer drugs, farnesyl transferase inhibitors and taxanes.
"GNS is committed to extending the use of our technology across many types of pharmaceutical drug development projects," said Colin Hill, CEO of GNS. "Our work with CombinatoRx stems from the unique value that the REFS™ approach offers in the development of truly novel combination therapies."
